Avid Bioservices, Inc. (CDMO) Research
Avid Bioservices, Inc. operates as a Contract Development and Manufacturing Organization (CDMO), specializing in the development and CGMP-compliant production of biopharmaceutical drug substances. Their core expertise lies in compounds derived from mammalian cell culture, providing both clinical and commercial scale manufacturing solutions. The company is proficient in producing critical therapeutics such as monoclonal antibodies and recombinant proteins. Beyond manufacturing, their comprehensive service portfolio encompasses CGMP manufacturing for drug substances, bulk packaging, rigorous release and stability testing, and essential regulatory submission and support. Additionally, Avid Bioservices offers a range of process development services, including the optimization of upstream and downstream processes, alongside the development, testing, and characterization of analytical methods. Avid Bioservices primarily serves clients within the biotechnology and biopharmaceutical industries. The company, which was originally incorporated in 1981, was known as Peregrine Pharmaceuticals, Inc. before officially rebranding to Avid Bioservices, Inc. in January 2018. Its corporate headquarters are situated in Tustin, California.
Market snapshot
- Symbol
- CDMO
- Price
- $12.49
- Day change
- 0.00%
- Market cap
- $798.9M
- P/E ratio
- -5.61x
- 52-week range
- 5.9-12.51
- Sector
- Healthcare
- Industry
- Biotechnology
- Analyst price target
- $8.00
Peer companies
Recent insider activity
- Ziebell Mark R — D-Return (14286 shares) on 2025-02-05
- Ziebell Mark R — D-Return (21429 shares) on 2025-02-05
- Ziebell Mark R — D-Return (1733 shares) on 2025-02-05
- Ziebell Mark R — D-Return (98120 shares) on 2025-02-05
- Ziebell Mark R — D-Return (17679 shares) on 2025-02-05
Open Avid Bioservices, Inc. (CDMO) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.